Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study

Creative Medical Technology highlighted six-month data from a 30-patient study of its Ultrasome™ cell-free regenerative platform in knee osteoarthritis, with 28 of 30 patients (93%) meeting study-defined response criteria. Average pain scores fell approximately 65% from baseline, WOMAC scores declined 52%, and no serious adverse events were reported during follow-up. The study was open-label and single-arm with no randomized or sham-controlled comparator, and Ultrasome is not FDA-approved; full findings are planned for peer-reviewed publication.

•14d ago

Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing

Creative Medical Technology Holdings (NASDAQ: CELZ) filed a new U.S. provisional patent application to broaden intellectual property protection around Ultrasome, its proprietary cell-free regenerative medicine platform. The filing seeks coverage across product composition, biological potency, manufacturing and quality control, stability, delivery methods and therapeutic applications, and builds on an April 2026 pilot study in which approximately 93% of knee osteoarthritis participants showed clinically meaningful improvement with no serious adverse events. Caveats are explicit: the provisional application has not been examined by the USPTO, there is no assurance any patent issues, and the FDA Drug Master File covering the underlying Olastrocel cell bank does not itself constitute regulatory approval.

•1mo ago

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

Creative Medical Technology Holdings announced the completion of enrollment and treatment across all cohorts of its ADAPT trial for CELZ-201 (Olastrocel), including an FDA-cleared opioid expansion cohort. Interim data from the trial demonstrated statistically significant improvements in functional disability and pain reduction, with an independent Data Safety Monitoring Board confirming a favorable safety profile. With the trial transitioning to follow-up, the company expects a meaningful decrease in clinical execution costs, which should extend its operating runway and support Phase 3 planning and RMAT evaluation without immediate fundraising.

•2mo ago

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

Creative Medical Technology Holdings received a Notice of Allowance from the USPTO for a patent application covering exosome-based immunotherapy for Type 1 diabetes, strengthening IP protection for its MyeloCelz platform. The allowed claims cover the use of exosomes to suppress autoimmune attacks on pancreatic cells, complementing previously issued patents that extend protection into the 2040s for the CELZ-101 and CELZ-201 programs. Management highlighted a large market opportunity estimated at $18 billion globally, though the company's products remain investigational and have not yet received FDA approval.

•2mo ago

Creative Medical Technology Holdings Issues Mid-Year Update

Creative Medical Technology Holdings issued a mid-year update highlighting positive interim data for Olastrocel (CELZ-201), which demonstrated statistically significant improvements in disability and pain in the ADAPT trial for chronic lower back pain. The company also reported strong pilot results for its cell-free osteoarthritis program, Ultrasome™, where 93% of patients showed clinically meaningful improvements, and noted that the FDA cleared an expansion of the ADAPT trial for patients on low-dose opioids. Additionally, the CELZ-Biodefense platform advanced into a nationwide data collection phase targeting 1,000 veterans, implemented without new capital raises to preserve shareholder value.

•4mo ago

Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain

Creative Medical Technology received FDA clearance to expand its ADAPT trial for Olastrocel, adding a cohort of 15 patients using less than 90 mg per day of morphine equivalents. The expansion follows positive 180-day interim data showing statistically significant improvements in functional disability and pain, with the new cohort already more than 85% enrolled. Management is actively preparing for Phase 3 discussions with the FDA, targeting a broader chronic lower back pain indication without needing additional resources for this specific expansion.

•4mo ago

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Creative Medical Technology Holdings announced that Project PHOENIX has advanced into a nationwide AI-driven virtual data collection phase, targeting an initial cohort of at least 1,000 U.S. veterans exposed to burn pits and toxic hazards. The decentralized platform utilizes a mobile app and field-capable logistics to gather longitudinal health data and multi-omics profiles without requiring participants to travel to centralized sites. Management stated the initiative will leverage existing infrastructure and does not expect to require additional fundraising, aiming to build a proprietary data engine for future therapeutic discovery.

•4mo ago

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

Creative Medical reported a 93% response rate in a pilot study of Ultrasome, a cell-free regenerative therapy for knee osteoarthritis, with no serious adverse events. Derived from the company's CELZ-201 platform, Ultrasome aims to offer scalable, off-the-shelf treatment targeting a multi-billion dollar market affecting over 30 million U.S. adults. Management plans to expand clinical execution and evaluate strategic pathways for commercialization and partnerships following these results.

•6mo ago